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Background: The Bacillus Calmette–Guérin vaccine (BCG) 
has been associated with beneficial nonspecific effects on 
infant health. We aimed to examine the effect of BCG at birth 
on thymic size and the associations between thymic output, 
circulating lymphocytes, risk of infection, and thymic size.
Methods: In infants randomized to BCG or no BCG, thymic 
index (TI), and thymic/weight index (TWI) were measured by 
ultrasound at birth and at the age of 3 mo. T cell subpopula-
tions including CD4+ T cells, CD8+ T cells, and recent thymic 
emigrants (RTEs) were assessed by flow cytometry. Infections 
up to age 3 mo were parent-reported.
results: BCG vaccination did not affect thymic size at age 
3 mo, measured as TI. At birth, the number of lymphocytes, 
CD4+ T cells, CD8+ T cells, and RTEs were positively associated 
with TI and TWI. Furthermore, a reduced risk of infections up to 
age 3 mo was associated with a large thymic size at birth.
conclusion: We found no effect of BCG vaccination on 
thymic size. The positive association between thymic output, 
lymphocytes, reduced risk of infections, and TI/TWI suggests 
that assessment of TI/TWI by ultrasound may be a predictor of 
the immunological capacity in the newborn.
Both observational studies and recent randomized trials indicate that Bacillus Calmette-Guérin vaccination (BCG) 
is associated with beneficial nonspecific effects (NSEs) (1–6), 
reducing mortality from infections other than tuberculosis. 
The immunological mechanisms underlying NSEs are not 
clear (7). Recent studies by Kleinnijenhuis et al. suggest that 
“trained immunity” mediated via functional reprogramming 
of the monocytes may play an important role (8). Effects on the 
adaptive immune system are also a possibility (9,10).
The thymus is essential in the generation and maturation of 
T cells and therefore, also in generating a normally functioning 
immune system (11). The size of the thymus has been shown 
to be important for infant survival in low-income countries. In 
Guinea-Bissau thymic size at birth, measured as thymic index 
(TI), was found to have a stronger association with survival 
than body weight (12), and among 6-mo-old children, a dou-
bling of the thymic size was associated with a 72% reduction in 
mortality up to 3 y of age (13).
Based on the facts that both BCG vaccination and a large 
thymus have been associated with increased infant survival, 
we hypothesized that the BCG-induced beneficial nonspecific 
effects were mediated by increasing thymic size.
Within The Danish Calmette Study, a randomized clinical 
trial testing the effect of receiving BCG vs. no BCG at birth 
on health outcomes (14), we tested the hypothesis that BCG 
vaccination at birth results in increased thymic size, absolutely 
and relatively, by 3 mo of age. Furthermore, we evaluated the 
association between thymic output and thymic size, and the 
association between episodes of infections in the first 3 mo of 
life and thymic size at birth.
METHODS
Overall Setting and Study Design
This study was nested within The Danish Calmette Study, which was 
conducted between October 2012 and January 2015, and has been 
described in detail elsewhere (14). In brief, The Danish Calmette 
Study is a randomized clinical multicenter trial with 1:1 allocation 
of 4,262 infants to either BCG vaccination or no BCG vaccination 
within 7 d of birth. The inclusion criteria were gestational age ≥ 32 wk 
and a birth weight ≥ 1,000 g. Exclusion criteria were maternal intake 
of immune modulating medicine during pregnancy, severe illness, or 
major malformations. The intervention group was vaccinated intra-
dermally with BCG vaccine (SSI strain 1331), in the standard dose 
of 0.05 ml in the upper, lateral part of the left shoulder. Background 
information on demographics and risk factors were collected by a 
structured telephone interview conducted in the third trimester of 
pregnancy.
Study Population
From March to November 2013, all children born at Copenhagen 
University Hospital, Hvidovre were invited to participate in this sub-
study including a thymus scan at randomization and at 3 mo follow up. 
By coincidence, none of the children were preterm children, hence our 
study population consisted of term (born between gestational weeks 
37 + 0 to 41 + 6) children only. A subgroup of these infants were further 
included into a substudy on T and B cells (N.M. Birk et al. The effect 
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of neonatal Bacillus Calmette-Guérin vaccination on T and B lympho-
cyte subsets: a clinical randomized trial (unpublished data) and had 
blood samples collected for flow cytometry analyses (Figure 1).
Baseline Measurements
Immediately following randomization the children had their thymic 
size measured by ultrasound. This was again immediately followed by 
vaccination of the BCG group. The blood sample used for measuring 
T and B cells cell subsets by flow cytometry was collected 4 d (± 2d) 
after the randomization, ultrasound examination, and vaccination.
Follow-up
At 3 mo of age, before having received any standard childhood vac-
cines, all infants were invited for a clinical examination at the hospi-
tal preceded by a follow-up telephone interview including questions 
about number of illness episodes in the first 3 mo of life. Questions on 
episodes of illness were designed to target illness due to infections (15) 
and parents were encouraged to take notes of their child’s illness in a 
diary supplied by study staff at the time of randomization. As part of 
the clinical examination, thymic size was assessed again. Following the 
clinical examination, another blood sample was obtained (Figure 1).
Ultrasound Examination of the Thymus
By transsternal ultrasound, thymic size was estimated as thymic 
index (TI) and thymic weight index (TWI), an absolute and relative 
volume estimate, respectively. First, the thymus gland was identified 
in a horizontal scanning plane and the largest transverse diameter 
of the thymus was obtained (Figure 2a). Second, in a sagittal scan-
ning plane, the area of the largest lobe was assessed (Figure 2b). Both 
measurements were obtained twice, and in case of more than 15% 
difference, both measurements were repeated. The means of each of 
the two measurements were multiplied and the value was defined as 
the thymic index (cm3) (16). For the weight-adjusted index TWI, TI 
was divided by weight of the child in kilograms (cm3/kg). All mea-
surements were conducted with a Sonosite MicroMaxx transportable 
ultrasound scanner with an 8–5 MHz C11e transducer, manufactured 
by SonoSite, Bothell, WA.
As thymus scans were performed by two investigators and interob-
server variation has been reported (12), the potential interobserver 
variation in this study was assessed; we found no significant differ-
ence between observers (Supplementary Methods S1 online).
T Cell Subsets, Flow Cytometry, and Lymphocytes
For the measurement of lymphocytes, blood was collected in 
K2EDTA (ethylenediaminetetraacetic acid) tubes (Greiner Bio-
One, Kremsmünster, Austria). Differential white blood cell count 
was measured by standard technique using a Sysmex XE-5000 at 
the Department of Clinical Biochemistry, Copenhagen University 
Hospital, Hvidovre, Denmark.
CD4+ T cells, CD8+ T cells, CD4+ RTEs (CD4+CD45RA+CD31+), 
and CD8+ RTEs (CD8+CD45RA+CD31+) were measured in periph-
eral blood using a 6-color FACS Canto (Becton Dickinson (BD), 
Franklin Lakes, NJ) and data were processed using FACS Diva soft-
ware (BD). In brief, 100 µl of EDTA blood was incubated with fluo-
rescent dye-conjugated monoclonal antibodies at room temperature 
for 20 min according to the manufacturer’s instructions. Erythrocytes 
were then lysed with 2 ml of Lysing Solution (BD) at room tempera-
ture for 20 min, and samples were washed and resuspended in FACS 
Flow (BD). Monoclonal antibodies used were isotype control IgG1 
peridinin chlorophyll proteins–cyanine (PerCP-Cy5.5), IgG1 fluores-
cein isothiocyanate (FITC),IgG2b allophycocyanin (APC), and IgG1 
allophycocyanin combined with an analog of Cy7 (APC-H7) further 
CD8-PerCPCy5.5, CD31-FITCH, CD45RA-APC, and CD4-APC-H7 
all purchased from BD.
Power Calculation
A post hoc power calculation was conducted based on previous work 
with thymic index, where mean TI in infants at 4 mo of age was 
3.0 cm3 (SD 1.5). To detect a difference of 20% in the intervention 
group, we needed to include 132 in each group; thus the number of 
included infants (156 in the intervention group and 158 in the control 
group) provided suitable power (α: 0.05, β 0.9, two-sided test).
Statistical Methods
To obtain normal distribution, TI and TWI were log-transformed. 
The primary estimate of the BCG-effect on TI was the geometric 
mean ratio (GMR) with 95% confidence interval (CI) obtained as 
the anti-logged coefficient from a linear regression with log-TI as 
outcome and randomization group and baseline log-TI as covari-
ates. The primary estimate of the BCG-effect on TWI was obtained 
similarly. The interpretation of a TI GMR of eg.1.15 being that chil-
dren randomized to BCG vaccination had a 15% larger TI than their 
controls.




Thymus scan at the time of
randomization
Thymus scan and blood




Thymus scan, n = 156
Blood sample, n = 53
Thymus scan, n = 158
Blood sample, n = 59
Thymus scan, n = 153
Blood sample, n = 53
Thymus scan, n = 3
Blood sample, n = 0
Lost to follow-up
Thymus scan, n = 10
Blood sample, n = 6
Thymus scan, n = 148
Blood sample, n = 53
Blood sample 4 d post
randomization
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We had few missing values of both outcome variables and covari-
ates, and complete case analyses were done; i.e., we included only chil-
dren for whom all information was available.
On the basis of previous findings of BCG having more pronounced 
beneficial nonspecific effects in girls (17), both overall and sex-strati-
fied primary outcome estimates were calculated. Furthermore, we had 
prespecified that we would investigate potential effect modification by 
gestational age, birth weight, cesarean section, antibiotics given to the 
mother during labor, maternal BCG, ethnicity of the parents, atopic 
predisposition, siblings, and age at randomization (day 0–1 vs. 2–7).
The analysis of the association between T cells, lymphocytes, and 
TI/TWI was done using linear regression analysis with absolute 
cell count and lymphocytes as outcomes, and log2-TI/log2-TWI as 
covariates. Cell measurements were done 4 d postrandomization, so 
we adjusted for BCG/no BCG.
The analysis of the association between episodes of illness and TI/
TWI was assessed in Poisson regression test for trend using a categor-
ical variable of none or at least one episode of parent-reported illness 
during the first 3 mo as outcome and TI/TWI as quartiles and sex as 
covariates. These analyses were adjusted for BCG/no BCG.
All analyses were performed using STATA 13.1 (StataCorp LP, 
College Station, TX).
Ethical Considerations
This study was approved by the Committees on Biomedical Research 
Ethics (J.no. H-3-2010-087), the Danish Data Protection Board (J.no. 
2009-41-4141), and the Danish Medicines Agency (J.no. 2612–4356.
EudraCT 2010-021979-85. Protocol 2009–323).
The study was registered at http://www.clinicaltrials.gov with regis-
tration number NCT01694108. The trial was supervised by the Good 
Clinical Practice Units of the Capital Region, Denmark and moni-
tored by an independent Data Safety Monitoring board.
The ultrasound examination did not cause any discomfort in the 
infants and is not known to be associated with any adverse events 
(18). Infants were included after both oral and written information 
was provided and a signed consent form from both parents was 
obtained. The study was conducted according to The Declaration of 
Helsinki.
RESULTS
A total of 314 healthy term infants were included in the study 
and had an ultrasound examination of the thymus at birth, 156 
were randomized to BCG and 158 to no BCG.
The two groups had similar baseline characteristics although 
infants in the BCG group were on average 0.11 kg heavier at 
birth (P = 0.04) (Table 1). At baseline, the two groups had 
similar thymic size, the GMR in the BCG vs. the control group 
being 1.02 (0.95–1.09) for TI and 0.99 (0.93–1.05) for TWI 
(Table 2).
Parents of 1% of the infants (3/314) withdrew consent to par-
ticipate and 3% (10/314) were lost to follow-up. There was no 
significant difference in the proportion of dropouts between 
groups (BCG 2% (n = 3) vs. no BCG 6% (n = 10), P = 0.09) 
(Table 1).
The remaining 301 infants were scanned at 3 mo follow-
up (mean age = 90 d). There were no significant differences 
between groups with regard to age, weight, breastfeeding, par-
ent-reported illness at follow-up, or general practitioner con-
sultations (GP) (Table 1).
The GM of TI was 12.8 vs. 12.6 (cm3) in the BCG group vs. 
the control group at birth, and 33.0 vs. 34.2 (cm3) at follow-
up. For TWI, it was 3.6 vs. 3.7 (cm3/kg) at birth, and 5.4 cm3 
vs. 5.6 (cm3/kg) at follow-up, respectively (Table 2). Useful 
Figure 2. Sonograms. Ultrasonic assessment of thymic size. An immuno-
logical evaluation within The Danish Calmette Study randomizing infants to 
BCG or no BCG at birth. (a) In a horizontal scanning plane the thymus is seen 
as an echo-poor structure surrounded by its echo-rich capsule surround-
ing the big vessels (Pulmonary artery and Ascending aorta).The largest 
transverse diameter of the thymus is measured (dashed line). (b) In a sagittal 
scanning plane, the area of the largest lobe is assessed (dashed line).
a b
Ultrasonic assessment 
table 1. Background characteristics at baseline and at follow-up 3 mo 
later in infants randomized to BCG or no BCG at birth
Baseline
BCG No BCG
P valuen = 156 n = 158
Age at randomization (days)a 1 (1–6) 1 (1–5) 0.35
Sex (male)b 86 (55 %) 86 (54 %) 0.9
Gestational age (weeks)a 40 (38–41) 40 (38–41) 0.51
Weight (kg)a 3.5 (3.0–4.2) 3.5 (2.8–4.1) 0.04
Cesarean sectionb 29 (19 %) 43 (27 %) 0.07
Maternal BCGb 33 (21%) (1) 30 (19%) 0.67
At least one parent of non-Danish 
ethnicityb
21 (13%) 30 (19%) 0.24
Maternal smoking during 
pregnancyb
12 (8%) 11 (7%) 0.82
Level of maternal educationb (1) (1) 0.77
Basic schooling and 
nontheoretical education
30 (19%) 34 (22%)
Theoretical education incl BA 
level
69 (45%) 72 (46%)
Master level or more 56 (36%) 51 (32%)
Siblingsb 62 (40%) 55 (35%) 0.37
Atopic predispositionc 103 (66%) 88 (56%) 0.06
Follow-up at 3 mo n = 153 (3) N = 148 (10)
Age at clinical examination 
(days)a
90 (83–100) 89 (82–102) 0.51
Weight (kg)a 6.1 (5.2–7.2) 6.1 (5.2–7.2) 0.55
Exclusively breastfeed at 3 mob 95 (62%) 84 (57%) 0.35
Number of parent reported 
infections ≥ 1b
9 (6%) 16 (10%) 0.15
Number of visits to the general 
practitioner ≥ 1b
49 (32%) 62 (42%) 0.08
Lost to follow-upb 3 (2%) 10 (6%) 0.09
aMedian (10–90 percentiles) (not available). b N number (Frequency) (not available). 
cAtopic predisposition is defined as at least one first degree relative with atopic disease. 
Atopic disease is defined as physician-diagnosed atopic eczema, asthma, allergic 
rhinoconjunctivitis, or food allergy.
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measurements were obtained for all children at baseline and 
at follow-up.
Effect of BCG on TI/TWI
No difference in thymic size at follow-up was found when 
comparing the BCG and the control group with regard to 
TI, the GMR being 0.96 (0.89–1.02), and TWI (GMR: 0.96 
(0.90–1.02)) (Table 2). Adjusting for weight at baseline did not 
change the estimates (data not shown).
Potential Effect Modification
No effect modification by sex on the effect of BCG on TI at fol-
low-up was found. The GMR was 0.92 (0.84–1.01) in males and 
0.98 (0.90–1.09) in females, P = 0.30 for interaction (Table 2). 
The same was seen for TWI (Table 2).
For children with no siblings, BCG was associated with a 
smaller TI (GMR: 0.92 (0.84–0.99)), P value for interaction = 
0.07, and a smaller TWI (GMR: 0.91 (0.85–0.99)) at 3 mo of 
age, P value for interaction = 0.05 (Table 3). None of the other 
pre-specified effect modifiers influenced the effect of BCG 
(Table 3).
Association Between T Lymphocyte Cell Subsets, Lymphocytes, 
and TI/TWI
At birth, we found a positive association between CD4+ T 
cells, CD8+ T cells, CD4+ recent thymic emigrants (RTEs), 
CD8+ RTEs, lymphocytes (n = 112), and TI (Figure 3). The 
positive association was stronger when looking at CD4+ T cells 
and TWI (Regression coefficient (a): 973 cells/µl per doubling 
of TWI, 95% CI 561–1,386, P < 0.001), CD8+ T cells (a: 146 
cells/µl pr. doubling of TWI, 95% CI 4–287, P = 0.044), CD4+ 
RTEs (a: 595 cells/µl pr. doubling of TWI, 95% CI 323–867, P 
< 0.001), CD8+ RTEs (a: 154 cells/µl pr. doubling of TWI, 95% 
CI 16–292, P = 0 .028), and lymphocytes (a: 1,498 cells/µl pr. 
doubling of TWI, 95% CI 924–2,072, P < 0.001). The inter-
pretation being that a doubling of TWI increases circulating 
lymphocytes by 1,498 cells/µl. At 3 mo of age, there were no 
associations between cell subsets (n = 106) and TI/TWI (data 
not shown).
Association Between Episodes of Infectious Diseases and TI/TWI
When looking at the association between infections assessed as 
none or at least one episode of infections during the first 3 mo of 
life and thymic size at birth in quartiles, a test for trend showed 
that with each step up in quartile, the incidence of infections 
decreased by 25% (RR: 0.75, 95% CI 0.55–1.05, P = 0.09 for 
TI); and 27% (RR: 0.73, 95 % CI 0.54–0.99, P = 0.04) for TWI. 
Compared with children in the three lower quartiles of TI, the 
children in the highest quartile had a 58% (IRR 0.42, 95% CI 
0.13–1.35, P = 0.20) decrease in risk of infections; for TWI it 
was 75% (IRR 0.25, 95% CI 0.06–1.03, P = 0.05) (Figure 4). 
We found no association between number of general practitio-
ner consultations and TI/TWI (data not shown).
DISCUSSION
BCG vaccination at birth did not affect thymic size, assessed 
by ultrasound as TI and TWI at birth and in 3-mo-old infants. 
Thymic size at birth was associated with increasing numbers of 
circulating lymphocytes and T cell subsets recently generated 
in the thymus as well as with reduced risk of parent-reported 
infections.
Strengths of this study were the randomized design, the low 
drop-out rate (4%), and that examiners were blinded. This 
study was not designed to assess the associations between T 
cells, infections, and TI/TWI. However, the analyses represent 
an internal quality control in this study and the associations 
are in line with previous findings. The overall number of infec-
tions in the first 3 mo of life is low and numbers were parent 
reported, representing a potential weakness in the assessment 
of the association between infections and thymic size.
To our knowledge, this is the first randomized trial testing 
the effect of BCG on thymic size in newborns in a high income 
country. In West Africa Eriksen et al. tested the effect of pro-
viding BCG at birth to low-birth-weight infants compared 
table 2. Overall and sex-specific effects of BCG vs. no BCG on thymic 
index (TI) and thymic weight index (TWI)





No BCG  
(n = 148) BCG vs. no BCG
Area of the largest lobe 
(cm2), at birth
4.0 4.0 –




diameter (cm), at birth
3.2 3.1 –
Largest transverse 
diameter (cm), at follow-up
4.3 4.3 –
TI (cm3) at birth
Overall 12.8 12.6 1.02 (0.95–1.09) 0.61
Males 12.9 12.8 1.01 (0.92–1.10) 0.71c
Females 12.7 12.3 1.03 (0.93–1.14)
TI (cm3) at follow-up
Overall 33.0 34.2 0.96 (0.89–1.02) 0.19
Males 34.0 36.9 0.92 (0.84–1.01) 0.30
Females 31.8 31.6 0.98 (0.90–1.09)
TWI (cm3/kg) at birth
Overall 3.6 3.7 0.99 (0.93–1.05) 0.66
Males 3.6 3.7 0.97 (0.90–1.05) 0.57
Females 3.6 3.6 1.01 (0.92–1.10)
TWI (cm3/kg) at follow-up
Overall 5.4 5.6 0.96 (0.90–1.02) 0.23
Males 5.3 5.8 0.94 (0.85–1.02) 0.35
Females 5.4 5.4 0.99 (0.91–1.09)
aGeometric mean. bGeometric mean ratio with 95% confidence interval. Follow-up 
estimates are adjusted for baseline, TI/TWI, and sex. cTest of interaction between BCG and 
sex.
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to the usual practice of postponing BCG until infants had 
reached a weight of 2.5 kg (Eriksen et al., “The effect of early 
Bacille Calmette-Guérin vaccine on thymic size in low birth 
weight infants in Guinea-Bissau”, personal communication.). 
Consistent with the present study, no overall or sex differential 
effect on TI or TWI after 4 wk was found. Caution in compar-
ing the two cohorts should be taken as inclusion criteria dif-
fered and the settings were different in many aspects (19).
We observed a tendency for BCG being associated with 
diminished thymic growth among children with no siblings, 
but not among children with siblings (Table 3). This may be 
caused by baseline differences; the BCG group had a smaller 
geometric mean in the “no siblings” group compared to the 
“siblings” group at baseline which seemed to be sustained at 
3 mo.
Thus, based on the existing studies, BCG does not exert non-
specific effects by modifying thymic size. With the introduction 
of the concept “Trained immunity” Kleinnijenhuis et al. chal-
lenge the paradigm that immunological memory after BCG is 
restricted to the adaptive immune response by showing that 
BCG induced an enhanced release of monocyte-derived cyto-
kines to unrelated pathogens, mediated by epigenetic repro-
gramming of innate immune cells independently of B and T 
cells (8). If the explanation for the observed beneficial NSEs of 
table 3. The effect of BCG at birth on thymic index/thymic weight index measured at 3 mo of age, stratified by baseline covariates
Thymic index Thymic weight index
BCG No BCG BCG No BCG
Effect modifiers n GMa at birth/3 mo GMRb 95% CI P valuec GM at birth/3 mo GMR 95% CI P value
Gestational age 301 1.00 (1.00–1.00) 0.20 1.00 (1.00–1.00) 0.22
Birthweight (kg) 301 1.00 (0.99–1.00) 0.25 1.00 (0.99–1.00) 0.32
Cesarean section 0.51 0.54
Yes 67 12.86/32.51 12.84/35.67 0.92 (0.79–1.06) 3.69/5.35 3.68/5.80 0.93 (0.81–1.06)
No 234 12.75/33.12 12.45/33.74 0.97 (0.90–1.05) 3.57/5.38 3.63/5.58 0.97 (0.91–1.05)
Antibiotics given to the 
mother during labor
0.83 0.75
Yes 68 12.53/34.22 13.14/36.56 0.97 (0.84–1.12) 3.61/5.55 3.71/5.82 0.98 (0.86–1.12)
No 233 12.85/32.66 12.40/33.60 0.95 (0.88–1.03) 3.60/5.33 3.63/5.59 0.96 (0.89–1.12)
Maternal smoking during 
pregnancy
0.61 0.47
Yes 21 13.05/35.12 12.98/34.32 1.02 (0.79–1.33) 3.68/5.89 3.71/5.63 1.05 (0.82–1.33)
No 279 12.75/32.83 12.53/34.20 0.95 (0.88–1.02) 3.59/5.34 3.64/5.63 0.96 (0.90–1.02)
Maternal BCG 0.61 0.47
Yes 61 12.69/35.42 12.62/36.20 0.99 (0.85–1.15) 3.63/5.78 3.72/5.90 1.01 (0.87–1.16)
No 237 12.78/32.31 12.57/33.82 0.94 (0.87–1.02) 3.59/5.27 3.64/5.58 0.95 (0.88–1.02)
At least one parent of 
non-Danish ethnicity
0.30 0.42
Yes 48 11.53/31.43 12.10/36.60 0.88 (0.74–1.05) 3.37/5.13 3.46/5.76 0.91 (0.77–1.06)
No 252 12.98/33.27 12.67/33.75 0.97 (0.90–1.05) 3.64/5.42 3.69/5.61 0.97 (0.91–1.04)
Atopic predispositiond 0.18 0.14
Yes 198 12.91/33.62 12.44/33.23 0.99 (0.80–1.01) 3.61/5.48 3.51/5.39 0.99 (0.92–1.08)
No 116 12.49/31.66 12.72/35.65 0.90 (0.81–1.01) 3.58/5.16 3.84/5.98 0.91 (0.81–1.00)
Siblings 0.07 0.05*
No siblings 190 11.99/31.56 12.29/34.95 0.92 (0.84–0.99) 3.45/5.23 3.58/5.79 0.91 (0.85- 0.99)
Siblings 111 14.08/35.39 13.09/32.92 1.04 (0.93–1.16) 3.83/5.63 3.78/5.63 1.04 (0.95–1.16)
Age at randomization
0–1 d 176 12.28/32.66 12.15/34.07 1.05 (0.96–1.15) 0.91 3.48/5.32 3.54/5.66 1.05 (0.97–1.14) 0.58
2–7 d 125 13.44/33.47 13.20/34.50 1.04 (0.94- 1.16) 3.76/5.46 3.81/5.61 1.02 (0.92–1.12)
aGeometric mean.
bGeometric mean ratio.
cP value for interaction between the allocation group and the potential modifier.
dAtopic predisposition is defined as a least one first degree relative with atopic disease. Atopic disease is defined as physician-diagnosed atopic eczema, asthma, allergic 
rhinoconjunctivitis, or food allergy.
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BCG is due to modulations of the innate immune response this 
could explain our finding of no effect on thymic size.
We found significant positive associations between the abso-
lute count of CD4+ RTEs, CD8+ RTEs CD4+ T cells, CD8+ T 
cells, lymphocytes, and thymic size in the newborn. This 
was strongest for lymphocytes, and stronger for the weight-
adjusted TWI compared to TI, indicating that a doubling in 
TWI increases the amount of circulating lymphocytes by 1,498 
cells/µl. This links neonatal thymic size to immune function. 
To our knowledge this is the first time an association between 
specific thymic output measured as RTEs and TI/TW has been 
shown. An association between proportions of CD8+ T cells 
but not CD4+ T cells and TI at 10 mo of age has earlier been 
shown (20), others found no correlation between proportions 
of CD4+ and CD8+ T cells and TI (21,22). RTEs constitute 
an early population of T cells recently generated in the thy-
mus and exported into the peripheral blood. Recently, it was 
reported that measuring CD4+ RTEs by flow cytometry, using 
CD31 as a surface biomarker as in our study, is as valid as mea-
suring T cell receptor excision circles (TRECs) with regard to 
evaluating thymic output (23). Our findings suggest that the 
used ultrasonic assessment of TI/TWI may be useful in evalu-
ating neonatal thymic output. A method which is noninvasive, 
considered safe (18), shown to be reproducible and correlate 
with autopsy findings of actual thymic volume (16). However, 
we are not able to conclude on the causality between thymic 
size, lymphocytes and risk of infection; hence it is possible that 
thymic size, T cells subsets and peripheral lymphocytes are all 
“barometers of good health,” but do not play a causal role in 
infants having fewer infections.
None of the infants in the present study were premature, low 
for gestational age, lymphopenic, or showed signs or symptoms 
of immunodeficiency. If the association between function and 
size of the thymus is similar in immunologically challenged 
Figure 3. Plots of the association between T cell subsets, lymphocytes, and thymic index in newborns randomized to BCG or no BCG. (a) The association 
between the absolute cell count (cells/μl) of recent thymic emigrants (RTEs) and TI at 4 d. The linear regression coefficient for CD4+ RTEs (filled circles) = 
523 cells/μl pr. doubling of TI, 95 % CI 281–764, P < 0.001 and for CD8+ RTEs (open circles) = 169, 95% CI 48–290, P = 0.007, n = 112. (b) The association 
between the absolute cell count (cells/μl) of CD4+ and CD8+ T cells and TI at 4 d. The linear regression coefficient for CD4+ (filled circles) = 849 cells/μl pr. 
doubling of TI, 95% CI 483–1,215, P < 0.001 and for CD8+ (open circles) = 165, 95% CI 41–290, P = 0.01, n = 112. (c) The association between the absolute 
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Figure 4. The association between thymic weight index at birth and 
subsequent infections in term infants. Infants are grouped into categories 
with none or at least 1 episodes of parent reported infections in the first 3 
mo of life. Thymic size is given as quartiles of thymic weight index at birth. 
Compared with children in the three lower quartiles of TI, the children in 
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infants, a small thymus at birth may result in a low peripheral 
T cell pool and a narrow T cell repertoire. This could provide a 
potential biological mechanism behind the findings of mortal-
ity being inversely related to thymic size (12,24). Several fac-
tors are known to affect thymic size, both in a thymopoietic 
(e.g., weight, gestational age, breastfeeding) and a thymolytic 
(e.g., infection, physiological stress, glucocorticoids and age) 
manner (25). The influence by several different factors on thy-
mic size might explain why the association between output 
and size becomes nonsignificant at age 3 mo.
Our results of reduced risk of infections in the first 3 mo 
of life with increasing thymic size at birth support findings 
of an association between infectious disease and thymic size. 
Previous studies have mainly shown that infections in a high 
income country lead to a smaller thymic size (26), but in this 
study we show that a larger thymic size at birth leads to fewer 
infections. This finding corroborates findings from West Africa, 
where a large thymic size was associated with reduced mortality 
(12,13). To our knowledge, this is the first time thymic size has 
been shown to potentially predict subsequent health measured 
as reduced number of infections in a high income country.
In conclusion, BCG vaccination at birth does not affect thy-
mic size at 3 mo of age measured as thymic index and thymic/
weight index in healthy term infants. Overall, the study sup-
ported that thymic size may be a marker of subsequent health 
due to less infectious disease, and demonstrated, for the first 
time, a positive association between thymic size and RTEs. 
Ultrasound to assess TI and TWI may be a useful way to iden-
tify immunologically vulnerable neonates in low income set-
tings where flow cytometry is not an option.
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